In this November/December issue of Cardiology Today’s Intervention, we cover one of the fastest-moving areas in endovascular intervention: catheter-based therapy for pulmonary embolism and deep vein thrombosis.
While in the past much effort in vascular medicine has focused on arterial disease — namely, peripheral artery disease — and, when appropriate, intervention, more recently vascular medicine has fully embraced treatment of venous disease, including with interventional techniques. The data for use of interventional techniques in both PE and DVT has certainly grown, though there is still a fair amount of controversy in terms of who exactly should get these invasive procedures. The challenge is sorting out who might benefit vs. conservative therapy with anticoagulation and in whom the potential bleeding risks of these procedures might be tolerated due to the presumed benefit. You will see a thorough discussion of the pros and cons of a more aggressive approach toward PE and DVT. We certainly need to do more in the way of large randomized clinical trials to resolve several contentious issues, but, until this happens, we will have to make do with what data exist and with clinical experience and expertise.
Also in this issue is a thorough recap of important and impactful trials from the European Society of Cardiology Congress in Munich. This particular ESC Congress was packed with new information and trials that have great potential to directly affect clinical care. In keeping with Cardiology Today’s Intervention’s expanded coverage of the vascular side of CV medicine, we also provide in this issue interesting meeting highlights from the Society for Vascular Surgery Annual Meeting, which was held in Boston. If that isn’t enough, read about some of the hottest trials from TCT in San Diego — with more to come in the January/February 2019 issue.
Let us know your thoughts on these issues by commenting at Healio.com/Intervention or emailing the Editors at email@example.com.